Practice guidelines for the prevention of venous thromboembolism in elderly patients hospitalized in acute care facilities;Recommandations pour la prévention de la maladie thromboembolique veineuse chez le patient âgé hospitalisé en services de soins de suite et réadaptation fonctionnelle (texte court)

Journal des Maladies Vasculaires

Volumn 28, Issue 4, 2003, Pages 209-218

  Bosson, J L ^a   Labarere, J ^b   Barrellier, M T ^b   Belmin, J ^b   Couturier, P ^b   Le Roux, P ^b   Sevestre, M A ^b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ARDEPARIN; ASPARAGINASE; BLOOD CLOTTING FACTOR 10A INHIBITOR; CREATININE; DALTEPARIN; ENOXAPARIN; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; REVIPARIN; TAMOXIFEN; TINZAPARIN; WARFARIN;

AGING; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL PRACTICE; CLINICAL TRIAL; COMPRESSION THERAPY; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG TOLERABILITY; GERIATRIC CARE; HEALTH CARE FACILITY; HEALTH CARE ORGANIZATION; HEALTH SERVICE; HOSPITALIZATION; HUMAN; IMMOBILIZATION; INTENSIVE CARE UNIT; INTERNATIONAL STANDARD UNIT; KIDNEY FAILURE; MEDICAL DECISION MAKING; META ANALYSIS; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; RISK ASSESSMENT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VEIN THROMBOSIS;

AGED; ANTICOAGULANTS; BANDAGES; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; IMMOBILIZATION; INFECTION; INSTITUTIONALIZATION; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; REHABILITATION CENTERS; THROMBOEMBOLISM; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 0142166862     PISSN: 03980499     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. ANDERSON FA, WHEELER HB, GOLDBERG RJ et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med, 1991; 151: 933-8.
2. GEERTS WH, HEIT JA, CLAGETT GP et al. Prevention of venous thromboembolism. Chest, 2001; 119: 132S-175S.
3. MISMETTI P, LAPORTE-SIMITSIDIS S, TARDY B et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost, 2000; 83: 14-9.
4. SAMAMA MM, COHEN AT, DARMON JY et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Pafients with Enoxaparin Study Group. N Engl J Med, 1999; 341: 793-800.
5. BOSSON JL, LABARERE J, SEVESTRE MA et al. Deep vein thrombosis in elderly patients hospitalized in subacute care facilities: risk factors, prophylaxis, and prevalence. A multicenter cross sectional study. Arch Intern Med, 2003; 163 (sous presse).
6. ANAES. Les recommandations pour la pratique clinique. Base méthodologique pour leur réalisation en France. Paris: Agence Nationale d'Accrédiation et d'Evaluation en Santé; 1999.
7. BERGQVIST D, BENONI G, BJORGELL O et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996; 335: 696-700.
8. PLANES A, VOCHELLE N, DARMON JY et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet, 1996; 348: 224-8.
9. DAHL OE, ANDREASSEN G, ASPELIN T et al. Prolonged thromboprophylaxis following hip replacement surgery-results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost, 1997; 77: 26-31.
10. LASSEN MR, BORRIS LC, ANDERSON BS et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty-the Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res, 1998; 89: 281-7.
11. MANGANELLI D, PAZZAGLI M, MAZZANTINI D et al. Prolonged prophylaxis with unfractioned heparin is effective to reduce delayed deep vein thrombosis in total hip replacement. Respiration, 1998; 65: 369-74.
12. HEIT JA, ELLIOTT CG, TROWBRIDGE AA et al. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann Intern Med, 2000; 132: 853-61.
13. HULL RD, PINEO GF, FRANCIS C et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med, 2000; 160: 2208-15.
14. COMP PC, SPIRO TE, FRIEDMAN RJ et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am, 2001; 83-A: 336-45.
15. HAENTJENS P. DELINCÉ PH and the Belgian Nadroparin Post-Hospital Discharge in Orthopaedics (NPHDO) study group. Prevention of venous thromboembolism after hospital discharge. Hip International, 2001; 11: 25-36.
16. BERGQVIST D, AGNELLI G, COHEN AT et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med, 2002; 346: 975-80.
17. PRANDONI P, BRUCHI O, SABBION P et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Arch Intern Med, 2002; 162: 1966-71.
18. LEVINE M, HIRSH J, GENT M et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet, 1994; 343: 886-9.
19. BERN MM, LOKICH JJ, WALLACH SR et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med, 1990; 112: 423-8.
20. MONREAL M, ALASTRUE A, RULL M et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices-prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost, 1996; 75: 251-3.
21. LAUSEN I, JENSEN R, JORGENSEN LN et al. Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. Eur J Surg, 1998; 164: 657-63.
22. EIKELBOOM JW, QUINLAN DJ, DOUKETIS JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet, 2001; 358: 9-15.
23. HULL RD, PINEO GF, STEIN PD et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med, 2001; 135: 858-69.
24. HARBOUR R, MILLER J. A new system for grading recommendations in evidence based guidelines. BMJ, 2001; 323: 334-6.
25. SARASIN FP, BOUNAMEAUX H. Antithrombotic strategy after total hip replacement. A cost-effectiveness analysis comparing prolonged oral anticoagulants with screening for deep vein thrombosis. Arch Intern Med, 1996; 156: 1661-8.
26. ROBINSON KS, ANDERSON DR, GROSS M et al. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the post-arthroplasty screening study. A randomized, controlled trial. Ann Intern Med, 1997; 127: 439-45.
27. NICOLAIDES AN, BREDDIN HK, FAREED J et al. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol, 2001; 20: 1-37.
28. BATH PM, IDDENDEN R, BATH FJ. Low-molecular-weight heparins and heparinoids in acute ischemic stroke: a meta-analysis of randomized controlled trials. Stroke, 2000; 31: 1770-8.
29. FAGOT JP, FLAHAULT A, KANFER A et al. Prévention de la maladie thromboembolique veineuse en milieu hospitalier non chirurgical. Presse Med, 2000; 29: 4-10.
30. RYAN TJ, ANTMAN EM, BROOKS NH et al. 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation, 1999; 100: 1016-30.
31. RIDKER PM, GOLDHABER SZ, DANIELSON E et al. Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism. N Engl J Med, 2003; 348: 1425-34.
32. THILLY N, PIERSON H, COLLARD C, LECOMPTE T, DUFAY E. Prévention de la maladie thromboembolique veineuse en milieu médical: de l'aide à la décision à l'utilisation des héparines de bas poids moléculaire. Therapie, 1998; 53: 579-86.
33. BERGMANN J, MAHE I. Prévention de la thrombose veineuse profonde en médecine. Ann Med Interne, 2000; 151: 207-14.
34. KISTNER RL, EKLOF B, MASUDA EM. Diagnosis of chronic venous disease of the lower extremities: the « CEAP » classification. Mayo Clin Proc, 1996; 71: 338-45.
35. PRANDONI P, PICCIOLI A, GIROLAMI A. Cancer and venous thromboembolism: an overview. Haematologica, 1999; 84: 437-45.
36. THODIYIL PA, WALSH DC, KAKKAR AK. Thromboprophylaxis in the cancer patient. Acta Haematol, 2001; 106: 73-80.
37. AMARAGIRI S, LEES T. Elastic stockings for prevention of deep vein thrombosis. The Cochrane Library, Oxford: Update Software; 2001.